Rick E Winningham has served as Chief Executive Officer and Chairman of the Board of Directors of Theravance Biopharma since its spin-off from Theravance, Inc. in June 2014. From October 2001 to August 2014, Mr. Winningham served as Chief Executive Officer of Theravance, Inc. Prior to joining Theravance, Inc., he served as President, Bristol-Myers Squibb (BMS) Oncology/Immunology/Oncology Therapeutics Network (OTN) from 1997 to 2001, and also as President of Global Marketing from 2000 to 2001. In addition to operating responsibility for U.S. Oncology/Immunology/OTN, Mr. Winningham also had full responsibility for Global Marketing in the Cardiovascular, Infectious Disease, Immunology, Oncology/Metabolics and GU/GI/Neuroscience therapeutic areas. Over a fifteen-year period with BMS and its predecessor, Bristol-Myers, Mr. Winningham held various U.S. and global management positions. During his tenure with BMS, he was associated with the development and commercialization of several major pharmaceutical products, such as Taxol®, Paraplatin®, Zerit®, Videx®, Reyataz®, and Abilify®.
Mr. Winningham holds an M.B.A. from Texas Christian University and a B.S. from Southern Illinois University. He is the Chairman of the Board of Directors of Theravance, Inc. and California Healthcare Institute (CHI) and a member of the Board of Directors of Jazz Pharmaceuticals. Mr. Winningham is also a member of Biotechnology Industry Organization’s Board of Directors, serving on the Health Section Governing Board and Board Standing Committee on Reimbursement.
Michael G. Atieh became a member of the Board of Directors of Theravance Biopharma, Inc. on June 2, 2014. Mr. Atieh was Executive Chairman of Eyetech Inc., a privately held specialty pharmaceutical company, from February 2009 until the company was acquired by Valeant Pharmaceuticals in February 2012. Previously, he was Executive Vice President and Chief Financial Officer of OSI Pharmaceuticals, a public biotechnology company, from 2005 until 2009. From 2001 to 2004 Mr. Atieh held the positions of Chief Financial Officer and Group President, Global Accounts Business Unit at Cegedim Dendrite, Inc., a public company specializing in developing and marketing databases and software for the healthcare field. Mr. Atieh spent the majority of his career with Merck & Co., Inc., a public pharmaceutical company, where he held various senior level positions over a 20 year period including Vice President—U.S. Human Health, Senior Vice President—Merck Medco Managed Care, Vice President—Public Affairs, Vice President—Government Relations, and Treasurer. Mr. Atieh currently serves on the board of directors of ACE Limited, a publicly traded global insurance company, where he chairs the Audit Committee and is a member of the Executive Committee. Mr. Atieh previously chaired the Audit Committee of OSI Pharmaceuticals from 2003 to 2005. Mr. Atieh holds a B.A. from Upsala College and became a qualified CPA in 1977.
Eran Broshy became a member of the Board of Directors of Theravance Biopharma, Inc. on June 2, 2014. Mr. Broshy has served as an operating partner with Linden Capital Partners, a private equity firm, since March 2013 and as an executive advisor with Court Square Capital, also a private equity firm, since March 2013. From June 2009 to December 2012, Mr. Broshy was a senior advisor to Providence Equity Partners, where he supported the private equity firm’s healthcare information investment efforts. Mr. Broshy previously served for over a decade as the Chief Executive Officer (until 2008) and chairman of the board of directors (until 2010) of inVentiv Health, Inc., a privately held company (and until August 2010 a Nasdaq listed company) that delivers a broad range of clinical and commercialization services to pharmaceutical and life sciences companies globally. Prior to joining inVentiv, Mr. Broshy was a management consultant with The Boston Consulting Group for 14 years, including as the partner responsible for BCG’s healthcare practice across the Americas for a number of years. He also served as President and Chief Executive Officer of Coelacanth Corporation, a privately held biotechnology company, from 1998 to 1999. He currently serves on the board of directors of Magellan Health Services, Inc., a public specialty health care management company, and within the previous five years Mr. Broshy has also served on the board of directors of two other public companies: inVentiv Health, Inc. and Neurogen Corporation, a biotechnology company. He also serves on the Simon Wiesenthal Center’s New York Executive Board, and on the Massachusetts Institute of Technology’s Visiting Committee for Brain and Cognitive Sciences, the Visiting Committee for Health Sciences & Technology, and the Dean of Science Advisory Council. Mr. Broshy holds an M.B.A. from Harvard University, an M.S. in civil engineering from Stanford University, and a B.S. in civil engineering from the Massachusetts Institute of Technology.
Dean J. Mitchell became a member of the Board of Directors of Theravance Biopharma, Inc. on June 2, 2014. Mr. Mitchell has served as Executive Chairman of the Board of Covis Pharma Holdings, a specialty pharmaceutical company, since August 2013, and on the Board of ImmunoGen Inc., a public oncology company, since 2012. Prior to that, Mr. Mitchell served as President and Chief Executive Officer of Lux Biosciences, Inc., a biotechnology company focusing on the treatment of ophthalmic diseases, from July 2010 to August 2013. Prior to Lux Biosciences, he served as President and Chief Executive Officer of both Alpharma, Inc., a publicly traded specialty pharmaceutical company, from 2006 until its acquisition by King Pharmaceuticals, Inc. in 2008, and Guilford Pharmaceuticals, Inc., a publicly traded pharmaceutical company focused in oncology and acute care, from 2004 until its acquisition by MGI Pharma Inc. in 2005. From 2001 to 2004 he served in various senior executive capacities in the worldwide medicines group of Bristol‑Myers Squibb Company, a pharmaceutical company. Prior to the Bristol‑Myers Squibb Company, he spent 14 years at GlaxoSmithKline plc, in assignments of increasing responsibility spanning sales, marketing, general management, commercial strategy and clinical development and product strategy. In addition to serving on the Covis Pharma Holdings board, Mr. Mitchell is also a current director of Intrexon, Inc., a biotechnology company, and, within the past five years, he also served as a director of each of Ista Pharmaceuticals, Inc., a specialty pharmaceutical company, Lux Biosciences, Inc. and Talecris Biotherapeutics Holdings Corp., a biopharmaceutical company and producer and marketer of plasma‑derived protein therapies. Mr. Mitchell holds an M.B.A. from City University London and a B.Sc. in biology from Coventry University.
Henrietta H. Fore became a member of the Board of Directors of Theravance Biopharma, Inc. in October 2013 and has served as a member of the Board of Directors of Theravance, Inc. from October 2010 until June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc.. Ms. Fore is Chairman of the Board and Chief Executive Officer of Holsman International, an investment and management company. From 2007 to 2009, Ms. Fore served as the Administrator of the U.S. Agency for International Development (USAID), and Director of United States Foreign Assistance, holding the equivalent rank as Deputy Secretary of State. In this position she was responsible for managing U.S. foreign assistance to countries recovering from disaster, trying to escape poverty, and engaging in democratic reforms. She also served on the Boards of the Overseas Private Investment Corporation, and the Millennium Challenge Corporation during this period. From 2005 to 2007, Ms. Fore served as Under Secretary of State for Management, the Chief Operating Officer for the Department of State, where she was responsible for the people, resources, facilities, technology and security of the Department and was the Secretary's principal advisor on management issues. Ms. Fore is a Trustee of the Aspen Institute and the Center for Strategic and International Studies. She serves on the Boards of Exxon Mobil Corporation, the Clinton Bush Haiti Fund, Committee Encouraging Corporate Philanthropy, Center for Global Development, and Women's Foreign Policy Group. She also serves on the Leadership Council of the Initiative for Global Development. She is Co-Chair of Women Corporate Directors, Asia Society Board of Trustees, and the Global Heritage Fund Diplomatic Council. Ms. Fore has a Bachelor of Arts degree in History from Wellesley College and a Master of Science degree in Public Administration from the University of Northern Colorado.
Robert V. Gunderson, Jr. became a member of the Board of Directors of Theravance Biopharma, Inc. in October 2013 and served as a member of the Board of Directors of Theravance, Inc. from July 2007 until June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc. He is a founding partner of the law firm of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, where he has practiced since 1995. Mr. Gunderson currently serves as a director of a number of private companies. Mr. Gunderson holds a J.D. from the University of Chicago, where he was Executive Editor of The University of Chicago Law Review. Mr. Gunderson also received an M.B.A. in Finance from The Wharton School, University of Pennsylvania and an M.A. from Stanford University.
Burton G. Malkiel, Ph.D. became a member of the Board of Directors of Theravance Biopharma, Inc. in October 2013 and served as a member of the Board of Directors of Theravance, Inc. from April 2010 until June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc. Dr. Malkiel, the Chemical Bank Chairman's Professor of Economics at Princeton University, is the author of A Random Walk Down Wall Street. He is also the author of over 125 articles and is the author or co-author of nine other books. From 1981 to 1988 he was dean of the Yale University School of Management and also served as the William S. Beinecke Professor of Management Studies. He is a past appointee to the President's Council of Economic Advisors. In addition, Dr. Malkiel currently serves on the board of directors of several corporations including The Vanguard Group Ltd. and Genmab. He also serves on several investment management boards including the Investment Committees for the American Philosophical Association and Alpha Shares, LLC. He is a past president of the American Finance Association and the International Atlantic Economic Association. He holds a B.A. and MBA degree from Harvard University and a Ph.D. degree from Princeton University.
Peter S. Ringrose, Ph.D. became a member of the Board of Directors of Theravance Biopharma, Inc. in October 2013 and served as a member of the Board of Directors of Theravance, Inc. from April 2010 until June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc. Dr. Ringrose was Chief Scientific Officer and President of Bristol Myers Squibb Pharmaceutical Research Institute from 1997-2002 and Senior Vice-President for Worldwide Drug Discovery at Pfizer Inc from 1982-1996. Since 2002 Dr. Ringrose has served as chair of the Biotechnology and Biological Sciences Research Council UK (2003-2009) and was a non-executive director of Cambridge Antibody Technology until its acquisition by Astra Zeneca in 2006. He is currently a non-executive director of Rigel Pharmaceuticals Inc., Astex Therapeutics Ltd. and Biotica Technology Ltd. Dr. Ringrose is a council member of the UK Foundation for Science and Technology and was a member the UK Government's Technology Strategy Board until 2009. Dr. Ringrose received a B.Sc., M.A. and Ph.D. from the University of Cambridge.
George M. Whitesides, Ph.D., became a member of the Board of Directors of Theravance Biopharma, Inc. in October 2013 and has served as a member of the Board of Directors of Theravance, Inc. from 1996 until June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc.He has been Woodford L. and Ann A. Flowers University Professor at Harvard University since 2004. From 1986 until 2004, Dr. Whitesides was Mallinckrodt Professor of Chemistry at Harvard University. From 1982 until 1991 he was a member of the Department of Chemistry at Harvard University and Chairman of the Department of Chemistry from 1986 until 1989. He was a faculty member of the Massachusetts Institute of Technology from 1964 until 1982. Dr. Whitesides was a 1998 recipient of the National Medal of Science. He is a member of the editorial boards of 14 scientific journals. He is also a member of the board of directors of Surface Logix, Inc., Nano-Terra Inc., Arsenal Biomedical, Inc., and Hughes Research Laboratories, L.L.C. In addition, in the past five years, Dr. Whitesides has served on the board of directors of Rohm and Haas Company. Dr. Whitesides holds a Ph.D. in Chemistry from the California Institute of Technology and a B.A. from Harvard University.
William D. Young became a member of the Board of Directors of Theravance Biopharma, Inc. in October 2013 and served as a member of the Board of Directors of Theravance, Inc. from April 2001 until June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc.Mr. Young served from 1999 until 2009 as Chairman of the board of directors and Chief Executive Officer of Monogram Biosciences, Inc. From 1980 to 1999 Mr. Young was employed at Genentech, Inc., most recently as Chief Operating Officer, where he was responsible for all Product Development, Manufacturing and Commercial functions. Prior to joining Genentech, Mr. Young worked at Eli Lilly and Company for fourteen years and held various positions in production and process engineering, antibiotic process development and production management. He is Chairman of the board of directors of Biogen Idec, Inc. Mr. Young received his M.B.A. from Indiana University and his B.S. in Chemical Engineering from Purdue University and an honorary Doctorate of Engineering from Purdue University. Mr. Young was elected to The National Academy of Engineering in 1993 for his contributions to biotechnology.